EP2604284A1 — Receptor And Antigen Targeted Prodrug
Assigned to VERGELL MEDICAL S.A. · Expires 2013-06-19 · 13y expired
What this patent protects
The present invention relates to a prodrug which comprises at least one pharmaceutically and/or diagnostically active compound bound by a cleavable linker, a receptor and/or antigen targeting moiety comprising a folic acid derivative and a protein-binding moiety which is capable …
USPTO Abstract
The present invention relates to a prodrug which comprises at least one pharmaceutically and/or diagnostically active compound bound by a cleavable linker, a receptor and/or antigen targeting moiety comprising a folic acid derivative and a protein-binding moiety which is capable of binding to a carrier molecule.
Drugs covered by this patent
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.